Skip to main content

Table 3 Selected studies for locally advanced pancreatic cancer employing chemoradiation ± chemotherapy

From: The role of radiotherapy in multimodal treatment of pancreatic carcinoma

Trial
(patients)
Chemotherapy* Radiotherapy (Gray) Median survival (months) p-value
Johnson[59]
(129)
Lithium Gamonelate - 5.4 n.a.
Maisey[56]
(44/46)
5/FU PVI
5-FU/MMC
- 32% 1 year
43% 1 year
n.a.
Louvet[60]
(47/50)
Gem
Gem/Ox
-
-$
10.3
10.3
p = n.s.
Rocha Lima[61]
(24/27)
Gem
Gem/Iri
-
-$
11.7
9.8
p = n.s.
Van Cutsem[62]
(80/82)
Gem
Gem/tipifarnib
- 8.7
11
p = n.s.
GITSG 1985[77]
(25/83/86)
-
5-FU
5-FU
60
40
60
5.2
9.6
9.2
p < 0.01
GITSG 1988[50]
(24/24)
SMF
SMF
54
-
6.5
5.1
p < 0.02
Klaassen[52]
(44/47)
5-FU
5-FU
40
-
8.3
8.2
n.a.
Chauffert[53]
(59/60)
5-FU(PVI)/Cis+Gem
Gem
60
-
8.0
14.5
p = 0.03
Loehrer[55]
(36/38)
Gem+ Gem
Gem
50.4
-
11.0
9.2
p = 0.034
Crane[66]
(53/61)
Gem
5-FU(PVI)
30 (10#) 11
9
p = n.s.
Li[78]
(18/16)
Gem
5-FU
50.4 14.5
6.7
p = 0.027
Ishii[63]
(20)
5-FU(PVI) 50.4 10.3 n.a.
McGinn[65]
(37)
Gem 24-42 11.6 n.a.
Shinchi[47]
(16/15)
5-FU(PVI)
Supportive care
50.4
-
13.2
6.4
n.a.
Brunner[67]
(40/42)
Gem/Cis+ Gem
Gem/Cis
55.8
55.8
13 8 p < 0.0001
Huguet[24]
(72/56)
5-FU(PVI)+ as below
FolFuGem, GemOx
55
-
15
11.7
p = 0.0009
Kachnic[64]
(23)
5-FU+ Gem 50.4 13 n.a.
  1. *: bold and italics indicate chemotherapy given as concurrent chemoradiotherapy #: radiotherapy fraction number; $: a chemotherapy only trial, but very few patients had some radiotherapy; 5-FU: 5-fluorouracil bolus injection unless marked as 'PVI'; Cis: cisplatin; Gem: gemcitabine; Fol: folinic acid; Iri: irinotecan; MMC: mitomycin C; n.a.: not available; n.s.: not significant; Ox: oxaliplatine; PVI: protracted venous infusion, SMF: streptozotocin, mitomycin, 5-fluorouracil.